A status update for a Phase 3 trial of elamipretide was recorded on May 20, 2026. The trial, known as ReNEW, is registered under identifier NCT06373731.
ReNEW is titled "Phase 3 Study of Efficacy, Safety and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)." It is evaluating subcutaneous injections of elamipretide in people with dry AMD.
According to the listing, the trial's current status is active but not recruiting. This means the study is ongoing but is not currently enrolling new participants.
The trial is designated Phase 3 and is examining efficacy, safety, and pharmacokinetics of the subcutaneous formulation in this patient population. No results have been posted in connection with this update.
Elamipretide currently carries approved regulatory status. This brief reflects only the trial status update as recorded on ClinicalTrials.gov and does not represent any outcome, efficacy, or safety conclusion.
Readers can consult the compound overview for additional context on elamipretide.